Adjuvant bisphosphonate treatment for breast cancer: Where are we heading and can the pre-clinical literature help us get there?

Journal of Bone Oncology

Volumn 1, Issue 1, 2012, Pages 12-17

  Russell, Kent ^a   Clemons, Mark ^a,b   Costa, Luis ^c   Addison, Christina L ^b,d  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c HOSPITAL DE SANTA MARIA   (Portugal)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adjuvant treatment; Bisphosphonate; Bone metastasis; Breast cancer; Preclinical models; Xenograft

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; DOXORUBICIN; ESTROGEN RECEPTOR; HORMONE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE P38; PAMIDRONIC ACID; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE; ZOLEDRONIC ACID;

BONE BIOPSY; BONE METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; COHORT ANALYSIS; DRUG EFFICACY; ESTROGEN DEFICIENCY; GAMMA DELTA T LYMPHOCYTE; HUMAN; IMMUNOMODULATION; MULTIPLE CYCLE TREATMENT; OSTEOLYSIS; POSTMENOPAUSE; REVIEW; TREATMENT OUTCOME;

EID: 84864208279     PISSN: 22121374     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbo.2012.04.003     Document Type: Review

References (47)

1. Powles T, Paterson A, McCloskey E, Schein P, Scheffler B, Tidy A, et al. Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]. Breast Cancer Research 2006;8:R13.
2. Diel IJ, Jaschke A, Solomayer EF, Gollan C, Bastert G, Sohn C, et al. Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up. Annals of Oncology 2008;19:2007-11.
3. Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. The Lancet Oncology 2011;12:631-41.
4. Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Stoeger H, Dubsky P, Jakesz R, et al. Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. In San Antonio Breast Cancer Symposium. December 6-10 2011, San Antonio, Texas; 2011.
5. Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, et al. Breast-cancer adjuvant therapy with zoledronic acid. New England Journal of Medicine 2011;365:1396-405.
6. Kristensen B, Ejlertsen B, Mouridsen HT, Jensen MB, Andersen J, Bjerregaard B, et al. Bisphosphonate treatment in primary breast cancer: results from a randomised comparison of oral pamidronate versus no pamidronate in patients with primary breast cancer. Acta Oncologica 2008;47:740-6. (Pubitemid 351878444)
7. Paterson AHG, Anderson SJ, Lembersky BC, Fehrenbacher L, Falkson CI, King KM, et al. NSABP protocol B-34: A clinical trial comparing adjuvant clodro-nate vs. placebo in early stage breast cancer patients receiving systemic chemotherapy and/or tamoxifen or no therapy-final analysis. In San Antonio Breast Cancer Symposium. December 6-10 2011, San Antonio, Texas. Edited by CTRC-AACR; 2011.
8. Thomssen Mobus V, Harbeck C, Untch N, Jackisch M, Diel C, Elling IJ, et al., GAIN (German Adjuvant Intergroup Node Positive) study: A phase III-multi-center trial to compare dose dense, dose intense etc (iddETC) vs. EC-TX and K. Russell et al. / Journal of Bone Oncology 1 (2012) 12-17 17 ibandronate vs. observation in patients with node-positive primary breast cancer'st interim efficacy analysis. In San Antonio Breast Cancer Symposium. December 6-10 2011, San Antonio, Texas. Edited by CTRC-AACR; 2011
9. Saarto T, Vehmanen L, Virkkunen P, Blomqvist C. Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in nodepositive breast cancer patients. Acta Oncologica 2004;43:650-6. (Pubitemid 39563937)
10. Padalecki SS, Guise TA. Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Research 2002;4:35-41. (Pubitemid 34097555)
11. Michigami T, Hiraga T, Williams PJ, Niewolna M, Nishimura R, Mundy GR, et al. The effect of the bisphosphonate ibandronate on breast cancer metastasis to visceral organs. Breast Cancer Research and Treatment 2002;75:249-58. (Pubitemid 35026118)
12. Sasaki A, Boyce BF, Story B, Wright KR, Chapman M, Boyce R, et al. Bispho- sphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice. Cancer Research 1995;55:3551-7.
13. Sasaki A, Kitamura K, Alcalde RE, Tanaka T, Suzuki A, Etoh Y, et al. Effect of a newly developed bisphosphonate, YH529, on osteolytic bone metastases in nude mice. International Journal of Cancer 1998;77:279-85. (Pubitemid 28287982)
14. Ottewell PD, Deux B, Monkkonen H, Cross S, Coleman RE, Clezardin P, et al. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo. Clinical Cancer Research 2008;14: 4658-66.
15. Yoneda T, Michigami T, Yi B, Williams PJ, Niewolna M, Hiraga T. Actions of bisphosphonate on bone metastasis in animal models of breast carcinoma. Cancer 2000;88:2979-88. (Pubitemid 30413180)
16. Hiraga T, Williams PJ, Ueda A, Tamura D, Yoneda T. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clinical Cancer Research 2004;10:4559-67.G (Pubitemid 38878900)
17. MayerLP, DevinePJ, DyerCA, HoyerPB. Thefollicle-depletemouseovary produces androgen. BiologyofReproduction2004;71:130-8. (Pubitemid 38915317)
18. Mayer LP, Devine PJ, Dyer CA, Hoyer PB. The follicle-deplete mouse ovary produces androgen. Biology of Reproduction 2004;71:130-8. (Pubitemid 38915317)
19. Chlebowski RT, Chen Z, Cauley JA, Anderson G, Rodabough RJ, McTiernan A, et al. Oral bisphosphonate use and breast cancer incidence in postmenopausal women. Journal of Clincal Oncology 2010;28:3582-90.
20. Rennert G, Pinchev M, Rennert HS. Use of bisphosphonates and risk of postmenopausal breast cancer. Journal of Clinical Oncology 2010;28: 3577-81.
21. Newcomb PA, Trentham-Dietz A, Hampton JM. Bisphosphonates for osteoporosis treatment are associated with reduced breast cancer risk. British Journal of Cancer 2010;102:799-802.
22. Wedin R, Skoog L, Bauer HC. Proliferation rate, hormone receptor status and p53 expression in skeletal metastasis of breast carcinoma. Acta Oncologica 2004;43:460-6. (Pubitemid 39037094)
23. Koenders PG, Beex LV, Langens R, Kloppenborg PW, Smals AG, Benraad TJ. Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The breast cancer study group. Breast Cancer Research and Treatment 1991;18:27-32.
24. Wei S, Li Y, Siegal GP, Hameed O. Breast carcinomas with isolated bone metastases have different hormone receptor expression profiles than those with metastases to other sites or multiple organs. Annals of Diagnostic Pathology 2011;15:79-83.
25. Journe F, Chaboteaux C, Dumon JC, Leclercq G, Laurent G, Body JJ. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells. British Journal of Cancer 2004;91:1703-10. (Pubitemid 39546144)
26. Hamilton E, Clay TM, Blackwell KL. New perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune response. Cancer Investigation 2011;29:533-41.
27. Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, et al. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Research 2011;71:4562-72.
28. Dhar S, Chiplunkar SV. Lysis of aminobisphosphonate-sensitized MCF-7 breast tumor cells by Vgamma9Vdelta2 T cells. Cancer Immunity 2010;10:10.
29. Meraviglia S, Eberl M, Vermijlen D, Todaro M, Buccheri S, Cicero G, et al. In vivo manipulation of Vgamma9 Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clinical and Experimental Immunology 2010;161:290-7.
30. Jagdev SP, Coleman RE, Shipman CM, Rostami HA, Croucher PI. Thebispho- sphonate, zoledronic acid, induces apoptosis of breast cancer cells:evidence for synergy with paclitaxel. British Journal of Cancer 2001;84:1126-34 (Pubitemid 32448513)
31. Ottewell PD, Monkkonen H, Jones M, Lefley DV, Coleman RE, Holen I. Antitumor effects of doxorubicin followed by zoledronic acid in amouse model of breastcancer. Journal of the National Cancer Institute 2008;100:1167-78.
32. Senaratne SG, Pirianov G, Mansi J L, Arnett TR, Colston KW. Bisphosphonates induce apoptos is in human breast cancer celllines. British Journal of Cancer 2000;82:1459-68. (Pubitemid 30175914)
33. Hiraga T, Williams PJ, Mundy GR, Yoneda T. The bisphosphonate ibandronate promotes apoptos is in MDA-MB-231 human breast cancer cells in bone metastases. Cancer Research 2001;61:4418-24. (Pubitemid 32685769)
34. Hiraga T, Ueda A, Tamura D, Hata K, Ikeda F, Williams PJ, et al. Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer. International Journal of Cancer 2003;106: 973-9. (Pubitemid 37071680)
35. Oades GM, Senaratne SG, Clarke IA, Kirby RS, Colston KW. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. Journal of Urology 2003;170:246-52. (Pubitemid 36734471)
36. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. British Journal of Urology International 2004;94:164-70. (Pubitemid 38980328)
37. Hussein O, Tiedemann K, Komarova SV. Breast cancer cells inhibit spontaneous and bisphosphonate-induced osteoclast apoptosis. Bone 2011; 48:202-11
38. Ory B, Moriceau G, Trichet V, Blanchard F, Berreur M, Redini F, et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. Journal of Cellular and Molecular Medicine 2008;12: 928-41. (Pubitemid 351718071)
39. Salomo M, Jurlander J, Nielsen LB, Gimsing P. How myeloma cells escape bisphosphonate-mediated killing: development of specific resistance with preserved sensitivity to conventional chemotherapeutics. British Journal of Haematology 2003;122:202-10. (Pubitemid 36859604)
40. Merrell M, Suarez-Cuervo C, Harris KW, Vaananen HK, Selander KS. Bisphosphonate induced growth inhibition of breast cancer cells is augmented by p38 inhibition. Breast Cancer Research and Treatment 2003;81:231-41. (Pubitemid 37352460)
41. Merrell MA, Wakchoure S, Lehenkari PP, Harris KW, Selander KS. Inhibition of the mevalonate pathway and activation of p38 MAP kinase are independently regulated by nitrogen-containing bisphosphonates in breast cancer cells. European Journal of Pharmacology 2007;570:27-37. (Pubitemid 47247687)
42. Kubo T, Shimose S, Matsuo T, Sakai A, Ochi M. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells. Cancer Chemotherapy and Pharmacology 2008;62:111-6. (Pubitemid 351537851)
43. Morii T, Ohtsuka K, Ohnishi H, Mochizuki K, Satomi K. Inhibition of heat-shock protein 27 expression eliminates drug resistance of osteosarcoma to zoledronic acid. Anticancer Research 2010;30:3565-71.
44. Thanner F, Sutterlin MW, Kapp M, Rieger L, Morr AK, Kristen P, et al. Heat shock protein 27 is associated with decreased survival in node-negative breast cancer patients. Anticancer Research 2005;25:1649-53. (Pubitemid 40896778)
45. Hansen RK, Parra I, Lemieux P, Oesterreich S, Hilsenbeck SG, Fuqua SA. Hsp27 overexpression inhibits doxorubicin-induced apoptosis in human breast cancer cells. Breast Cancer Research and Treatment 1999;56:187-96. (Pubitemid 29494836)
46. Oesterreich S, Weng CN, Qiu M, Hilsenbeck SG, Osborne CK, Fuqua SA. The small heat shock protein hsp27 is correlated with growth and drug resistance in human breast cancer cell lines. Cancer Research 1993;53:4443-8. (Pubitemid 23304358)
47. Kang SH, Kang KW, Kim KH, Kwon B, Kim SK, Lee HY, et al. Upregulated HSP27 in human breast cancer cells reduces herceptin susceptibility by increasing Her2 protein stability. BMC Cancer 2008;8:286.